Introduction
Bile acids are synthesized from cholesterol and act as detergents to promote the digestion and intestinal absorption of fats and fat-soluble vitamins. Bile acids also function as ligands for nuclear and G protein-coupled receptors and have important roles as signaling molecules. The best-studied bile acid receptors are the farnesoid X receptor (FXR) and G protein-coupled receptor 1 (also called TGR5 or membrane-type receptor for bile acids), but the list of bile acid receptors also includes other nuclear receptors, such as the pregnane X receptor and vitamin D receptor, and other G protein-coupled receptors, such as the sphingosine-1-phosphate receptor 2, and muscarinic receptors M2 and M3 [1, 2] . It is important to note that bile acids alsoAfter their synthesis in the hepatocyte, bile acids are secreted into bile and stored in the gallbladder or small intestinal lumen. In response to a meal, the gallbladder contracts and intestinal motility is stimulated. Bile acids then travel down the length of the small intestine to the ileum, where they are reabsorbed, and carried back to the liver in the portal circulation for uptake and resecretion into bile [7] . The enterohepatic circulation functions to safely store and then promptly deliver bile acids in high concentration to the intestinal lumen for digestion and absorption of lipids, while limiting the distribution and systemic signaling potential of these potentially cytotoxic detergent molecules. As a result of these tight pharmacokinetic controls, bile acid concentrations vary markedly between compartments in the body, ranging from high millimolar in the biliary tract and gallbladder, to low millimolar in the intestine and colon, to low micromolar in the systemic circulation [8] . The membrane carriers that maintain the enterohepatic circulation of bile acids are known and include specific transporters expressed on the sinusoidal and canalicular membranes of the hepatocyte, and on the apical brush border and basolateral membranes of the ileal enterocyte [9] . In ileum, the apical sodium-dependent bile acid transporter (Asbt or ibat; Slc10a2 ) and the heteromeric transporter Ostα-Ostβ (Ost = Organic solute transporter; Slc51a -Slc51b ) mediate these steps [10] . These transporters help determine the turnover of bile acid ligands and control access to the intracellular bile acid receptors in important target cells. Bile acids are synthesized from cholesterol via 2 pathways, the major classical pathway (Cholesterol 7α-hydroxylase, Cyp7a1, pathway) that favors cholic acid biosynthesis, and a minor alternative pathway that favors biosynthesis of chenodeoxycholic acid (in humans) or muricholic acid (in mice) [11] . The expression of Cyp7a1, the rate-limiting step in bile acid biosynthesis, is tightly controlled by a complex network of regulatory mechanisms and has been the subject of intensive study. Investigation beginning in the 1960s showed that hepatic bile acid synthesis and Cyp7a1 activity were suppressed after the administration of exogenous bile acids and induced when bile acid return to the liver was blocked by the administration of bile acid sequestrants or by biliary diversion [12] . This negative feedback regulation of Cyp7a1 was shown to be transcriptional and was shown to involve the bile acid-activated nuclear receptor FXR. Initially, it was thought that the mechanism for feedback regulation was restricted to FXR signaling in the liver. However, this model could not explain a series of puzzling experimental findings, including the observation that intravenous infusion of bile acids into bile-fistula rats was ineffective at downregulating hepatic Cyp7a1 expression compared to intraduodenal infusion of bile acids [13] .
More recent investigation determined that the major pathway for feedback regulation of bile acid synthesis under physiological conditions involves ileal FXR and gutliver signaling via the polypeptide hormone fibroblast growth factor-19 (FGF19; mouse ortholog: FGF15) [14] . FGF15/19 is a ∼ 25 kDa (216 amino acids in humans; 218 amino acids in mice) secreted protein, which acts not only locally but also systemically in an endocrine fashion. In the FXR-FGF15/19 pathway, the Asbt first transports bile acids from the intestinal lumen across the apical brush border membrane into the ileal enterocyte. Before their export from the cell via Ostα-Ostβ, bile acids bind and activate FXR, which induces transcription of FGF15/19. After its synthesis and release by the enterocyte, FGF15/19 is carried in the portal circulation to the hepatocyte where it binds a complex of the βKlotho accessory protein and FGF receptor-4 [15] . This initiates signaling via the docking protein fibroblast growth factor substrate 2 and a tyrosine phosphatase (tyrosine-protein phosphatase nonreceptor type 11; Shp2) to stimulate extracellular-signalregulated kinase (ERK1/2) activity and block activation of Cyp7a1 gene expression by HNF4α and LRH-1.
Changes in Asbt or Ostα-Ostβ expression have the potential to control the intracellular levels of bile acids and therefore influence FXR-mediated regulation of FGF15/19 production. This is effectively illustrated by comparing the effects of inhibiting ileal apical versus basolateral membrane bile acid transport on bile acid metabolism [16, 17] . As illustrated in figure 1 , inactivation of the Asbt in mice produces a classical severe bile acid malabsorption phenotype, whereby excretion of bile acids in the feces is increased by more than fivefold, whole body bile acid pool size is reduced, and whole body bile acid pool composition is altered. The ratio of taurocholate to tauromuricholate in the bile acid pool shifts from approximately 1: 1, which is typically found in wild type (WT) mice, to greater than 5: 1, suggesting a dramatic derepression of hepatic bile acid synthesis via the Cyp7a1 pathway [16] . In contrast to blocking apical bile acid uptake, inactivation of Ostα in mice failed to increase fecal bile acid excretion or significantly alter whole body bile acid pool composition. However, whole body bile acid pool size was reduced almost to the same extent as observed for the inactivation of the Asbt [17] . Overall, the phenotype suggested impaired regulation of hepatic bile acid synthesis and as illustrated in figure 2 , can be explained by alterations in gutliver FXR-FGF15 signaling. In Ostα -/-vs. Asbt -/-mice, total ileal FGF15 mRNA expression is increased almost tenfold, and this inversely correlates with approximately eightfold reductions in liver Cyp7a1 mRNA expression, ninefold reductions in liver microsomal Cyp7a1 enzyme activity, and sevenfold reductions in fecal bile acid excretion. Bile acids have been shown to modulate a variety of metabolic pathways involved in controlling glucose, lipid, and energy homeostasis. The regulation is complex and involves a variety of bile acid receptors and signaling pathways. This includes FXR-mediated control of glucose metabolism through the regulation of hepatic gluconeogenesis and glycogenolysis, control of intestinal glucose absorption, and actions in adipose and pancreas [18] [19] [20] . There is also an expanding role for TGR5. The bile acidactivated G-protein coupled receptor TGR5 is expressed by nonparenchymal cells of the liver, macrophages, brown adipose tissue, enteroendocrine cells, spinal and enteric neurons, and a variety of cell types in brain. At these different sites, TGR5 has actions that are anti-in- flammatory, increase energy expenditure [21] , modulate glucose metabolism [22] , control gallbladder filling and intestinal motility, and mediate itch and analgesia [23] . The bile acid receptors and mediators that contribute to these physiological and metabolic effects will vary depending in part on the enterohepatic circulation of bile acids. This is nicely illustrated by the finding of beneficial metabolic effects with the seemingly contradictory approaches of administering bile acids (or FXR agonists) or removing bile acids using a bile acid sequestrant. The beneficial metabolic actions of bile acids or FXR agonists may be mediated in part by the induction of ileal FGF15/19 production [24] . Several lines of evidence suggest that FGF15/19 functions as a postprandial hormone to regulate glucose metabolism [25, 26] . In addition, delivery of pharmacological doses of FGF19, either by transgenic overexpression or administration of recombinant FGF19 protein, induces resistance to diet-induced weight gain, increases metabolic rate, and improves glucose tolerance [27, 28] .
The opposite strategy of sequestering bile acids also decreases plasma glucose and increases insulin sensitivity in patients with type 2 diabetes [29] . The mechanisms responsible for the beneficial metabolic effects of bile acid sequestrants have been explored in mouse models. One line of evidence suggests that bile acid sequestrants induce hepatic bile acid synthesis and alter the bile acid species present in the systemic circulation, thereby increasing the activation of TGR5 in brown adipose tissue and increasing energy expenditure [30] . Interestingly, changes in systemic levels of different bile acid species have also been implicated in the beneficial metabolic effects of bariatric surgery [31] [32] [33] . A second line of evidence suggests that bile acid sequestrants act by increasing delivery to the colon of bile acids, which signal through TGR5 on enteroendocrine L-cells to increase production of GLP-1 [34, 35] , an incretin hormone with potent anti-diabetic actions. Finally, sequestering bile acids or blocking Asbtmediated uptake may produce beneficial metabolic effects by inhibiting FXR signaling in the intestine to reduce biosynthesis of intestinally derived ceramides. Although there is evidence that intestinal-selective FXR agonist has metabolic benefit [36] , other studies in high fat diet-fed mouse models suggest that activation of FXR in the intestine increases production of ceramides, which act systemically to stimulate Srebp1c-driven hepatic lipogenesis and reduce beige fat thermogenic function [37, 38] .
Role of Intestinal Bile Acid Transporters in Cytoprotection against Bile Acid-Induced Injury
The cellular and molecular mechanisms of hepatocyte injury caused by the retention of hydrophobic bile acids in cholestatic disease have been the subject of intensive study [39] . Bile acids can activate hepatocyte death recep- tors, induce generation of reactive oxygen species and oxidative damage, induce mitochondrial dysfunction, and endoplasmic reticulum stress. With regard to the transporters that maintain the enterohepatic circulation, bile acid-associated injury is perhaps best described for Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC2). In PFIC2, inherited mutations in the bile salt export pump ABCB11 lead to the loss of canalicular bile acid export, hepatocellular accumulation of bile acids, and subsequent injury [40] . By contrast, less is known regarding the mechanisms and signaling pathways underlying the potential cytotoxic effects of bile acids in other cell types and in extra-hepatic tissues [4, 5] . In theory, dysregulated expression of the Asbt and Ostα-Ostβ may lead to bile acid accumulation and injury in ileal enterocytes or in the bile acid transporting epithelium of the biliary tract and renal proximal tubules, which express the same complement of transporters. Important clues to those potential mechanisms of epithelial injury may come from the study of Asbt and Ostα-Ostβ deficiency. Loss-of-function ASBT mutations in humans or mice yield a classical primary bile acid malabsorption phenotype, with impaired intestinal bile absorption in the absence of ileal histological changes [16, 41, 42] . Although loss of Ostα-Ostβ expression also blocks intestinal bile acid absorption, the phenotype of Ostα -/-mice includes a dramatic remodeling of the ileal morphology, with features typically associated with epithelial damage and subsequent healing [17, 43] . The molecular mechanisms linking the imbalance of Ostα-Ostβ and Asbt expression and the altered ileal morphology have not yet been identified. However, a similar imbalance has also been described in some animal models of necrotizing enterocolitis, a disease characterized by necrosis of the distal ileum and proximal colon in premature infants [44] . Outside of Inflammatory Bowel Disease, Ileal atrophy is not often seen in the absence of duodenojejunal atrophy [45] . However, cases of apparent Primary Ileal Villous Atrophy (PIVA) and bile acid malabsorption of unknown etiology have been reported [46] [47] [48] . The relationship of the intestinal bile acid transporters to the pathogenesis of PIVA and similar disorders remains to be determined.
